logo
 

India's indigenously developed vaccine against coronavirus COVAXIN has demonstrated an interim vaccine efficacy of 81 per cent in its Phase 3 clinical trial. The trials involved 25,800 subjects, the largest ever conducted in India, in partnership with ICMR, informed vaccine maker Bharat Biotech.


Covaxin is India's totally indigenous COVID-19 vaccine developed in collaboration with the Indian Council of Medical Research and National Institute of Virology.


The vaccine is developed and manufactured in Bharat Biotech's BSL-3 (Bio-Safety Level 3) bio-containment facility, one of its kind in the world.


In Phase 1 and Phase 2 clinical trials, Covaxin demonstrated the ability to produce antibodies against Covid-19.

No Comments For This Post, Be first to write a Comment.
Leave a Comment
Name:
Email:
Comment:
Enter the code shown:


Can't read the image? click here to refresh
learn quran online easily

Todays Epaper

Latest Urdu News

Which political party will win the Nagarjuna Sagar Assembly by-poll to be held on April 17?

TRS
Congress
BJP